FA
AZN icon

Faithward Advisors’s AstraZeneca AZN Stock Holding History

Faithward Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,950
Closed -$460K – 263
2024
Q3 		$460K Sell
2,950
-80
-3% -$12.9K 0.08% 174
2024
Q2 		$473K Sell
3,030
-193
-6% -$29K 0.09% 171
2024
Q1 		$437K Buy
+3,223
New +$427K 0.08% 172

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Sanders Capital
Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return

Faithward Advisors's AZN Position: Q4 2024 in Review

Faithward Advisors sold out of AstraZeneca (AZN) in Q4 2024, closing a stake of 2,950 shares — an estimated $460K sold.

Faithward Advisors first reported a position in AZN in Q1 2024 and held it in 3 quarters. The position peaked at $473K in Q2 2024. 1,218 funds tracked by Wall St. Rank hold AZN as of Q4 2024.

  • Faithward Advisors reported no remaining AstraZeneca position as of Q4 2024 after selling out during the quarter.
  • Faithward Advisors sold 2,950 AstraZeneca shares in Q4 2024, an estimated $460K.
  • Faithward Advisors first reported a position in AstraZeneca in Q1 2024 and held it in 3 quarters.
  • Faithward Advisors's AstraZeneca position peaked at $473K in Q2 2024.
  • 1,218 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2024.

Based on Faithward Advisors's 13F filing for Q4 2024, filed 13 Feb 2025.